Literature DB >> 20099188

Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment.

Aurelie Cabrespine-Faugeras1, Mathilde Bayet-Robert, Jacques-Olivier Bay, Philippe Chollet, Chantal Barthomeuf.   

Abstract

Complementary and alternative therapies for neoplastic diseases treatment and prevention receive increasing attention from the medical community. Prostate cancer (PC) is the most frequently diagnosed malignancy and the second major cause of male death in industrialized countries. The chemopreventive properties and clinical safety of curcumin, a polyphenolic derivative, have already been established. However, curcumin regimen value in addition to conventional hormone refractory (HR) PC treatment remains largely unknown. This review article summarizes mechanisms by which curcumin may decrease HRPC aggressive proliferation and potentiate activity of taxane therapy. Our analysis suggests that curcumin alone has a therapeutic value in HRPC. In combination with a taxane agent, this compound may enhance cytotoxicity and retard PC cell resistance to taxane. As a consequence, a rationale is provided for considering the possible benefits of curcumin regimen in combination with taxane therapy in HRPC patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20099188     DOI: 10.1080/01635580903305383

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  5 in total

1.  Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer.

Authors:  Jiayi Yang; Jianping Ning; Linlin Peng; Dan He
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Effects of cyclohexanone analogues of curcumin on growth, apoptosis and NF-κB activity in PC-3 human prostate cancer cells.

Authors:  Xingchuan Wei; Zhi-Yun DU; Xiao-Xing Cui; Michael Verano; Rong Qing Mo; Zhi Kai Tang; Allan H Conney; Xi Zheng; Kun Zhang
Journal:  Oncol Lett       Date:  2012-05-10       Impact factor: 2.967

3.  Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy.

Authors:  Chen Cheng; Binglin Sui; Mingming Wang; Xiangxiang Hu; Shanshan Shi; Peisheng Xu
Journal:  Adv Healthc Mater       Date:  2020-09-06       Impact factor: 9.933

Review 4.  Recent progress on nutraceutical research in prostate cancer.

Authors:  Yiwei Li; Aamir Ahmad; Dejuan Kong; Bin Bao; Fazlul H Sarkar
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 5.  Polyphenols: key issues involved in chemoprevention of prostate cancer.

Authors:  Sebastiano Cimino; Giuseppe Sortino; Vincenzo Favilla; Tommaso Castelli; Massimo Madonia; Salvatore Sansalone; Giorgio Ivan Russo; Giuseppe Morgia
Journal:  Oxid Med Cell Longev       Date:  2012-05-28       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.